Biostem Technologies Inc (BSEM) 11.2000 $BSEM
BioStem Technologies, Inc. (OTC: BSEM) Announces Issuance of FDA Drug Establishment Registration Number and FDA Labeler Code to Wholly Owned Subsidiary BioStem Pharmaceuticals, Inc.
Marketwired - Thu Jun 02, 8:30AM CDT
OAKLAND PARK, FL--(Marketwired - Jun 2, 2016) - BioStem Technologies, Inc. ("BioStem" or the "Company"
(OTC PINK: BSEM) announced today that the FDA has accepted and issued BioStem Pharmaceuticals, Inc., a wholly owned subsidiary of the Company, its FDA Drug Establishment Registration Number and Labeler Code for Manufacturing and Repackaging of pharmaceutical products.
BioStem Technologies, Inc. (OTC: BSEM) Appoints David Wolfe and Dr. Michael Beckwith to Its Advisory Board
Marketwire Canada - Fri May 27, 9:31AM CDT
OAKLAND PARK, FL--(Marketwired - May 27, 2016) - BioStem Technologies, Inc. ("BioStem" or the "Company" (OTC PINK: BSEM) today announced the appointment of David Wolfe and Rev. Michael Bernard Beckwith to its Advisory Board. The Advisory Board of the Company provides advice and guidance to the Board of Directors of the Company, but Advisory Board members are not Directors of the Corporation. Mr. Wolfe and Dr. Beckwith are both well-known opinion leaders in their respective fields.
Biostem Technologies, Inc. (OTC: BSEM) Announces the Appointment of Dr. Dave Woynarowski as Chief Medical Officer
Marketwired - Mon Feb 01, 11:19AM CST
Dr. Dave Woynarowski was appointed Chief Medical Officer of Biostem Technologies, Inc. (OTC PINK: BSEM) effective immediately. Dr. Woynarowski received his medical degree from Temple University, and served as chief resident in his Internal Medicine Training program. He went on to become part of the resident education system, and twice receiving the prestigious Residents Teaching Award from his students and residents. He holds a Master's Degree in Physiology, and was a Certified Personal Trainer during his early medical career. He also served as Adjunct Professor to Hershey School of Medicine.
Biostem Technologies, Inc. (OTC: BSEM) Announces Commencement of International Operations in Guadalajara, Mexico
Marketwired - Thu Jan 28, 8:30AM CST
(OTC PINK: BSEM), Biostem Technologies, Inc. We are pleased to announce that Biostem Technologies, Inc. has entered into an agreement with Dr. Jesus Esparragoza Romano and his team in Guadalajara, Mexico to form the Mexican entity -- Bio ST Holdings, S. de R.L. de C.V. which is a wholly owned subsidiary of Biostem Technologies, Inc.
Biostem Technologies Completes Test-O-Shave Product Line Acquisition
PR Newswire - Fri Dec 11, 8:30AM CST
(OTC: BSEM), Biostem Technologies, Inc. is pleased to announce the acquisition of another product line. Biostem Technologies (BSEM) acquired this asset by virtue of a stock exchange valued at, $155,500. Test-O-Shave is a product line focusing on providing natural grooming and hygiene products. In addition to the men's line of products, Test-O-Shave produces organic soaps, creams, oils, and a women's shave line in development. What sets this product line apart is its natural testosterone boosting ingredients, Pine Pollen and Tribulus.1 It has been shown that bisphenol A (PBA), preservatives and other artificial ingredients can naturally decrease your testosterone levels.1 Therefore; Test-O-Shave, with it's all natural Pine Pollen and Tribulus may increase your natural testosterone levels.1 The Company will immediately re-brand this product line to its Bioshave brand to become the foundation of the Company's retail natural grooming and hygiene products.
Biostem Technologies, Inc. (OTC: BSEM) Announces Purchase of New Laboratory / Headquarters
PR Newswire - Mon Nov 16, 8:30AM CST
(OTC: BSEM), Biostem Technologies, Inc. is pleased to announce the purchase of its new research and development laboratory and headquarters. The building is located at 2836 Center Port Circle in Pompano Beach, FL. With frontage on I-95 and Copans Road, Center Port Business Park is strategically located nearly equidistant from Fort Lauderdale and Miami, to the south, and Boca Raton and West Palm Beach, to the north. The purchase price of Biostem's new laboratory and headquarters was $600,000 and projected build-out costs are estimated to be $700,000. The estimated grand opening for the completed facility is scheduled for March 1st, 2016.
BioStem Technologies Announces the Launch of our New Educational and Interactive Website
ACCESSWIRE - Thu Apr 09, 7:52AM CDT
OAKLAND PARK, FL / ACCESSWIRE / April 9, 2015 / BioStem Technologies, Inc. (OTC PINK: BSEM) announces newly created educational and interactive website set to go live today, April 9, 2015.
BioStem Technologies (BSEM) Announces Retirement of 128,979,751 Shares of Common Stock and the Issuance of Amended Series B-1
ACCESSWIRE - Thu Jan 08, 7:01AM CST
Oakland Park, FL / ACCESSWIRE / January 8, 2015 / Biostem Technologies, Inc. (BSEM), announces that it has officially retired 128,979,751 shares of common stock. Furthermore, the company has amended its Series B-1 shares. The retiring of the 128,979,751 common shares to treasury reduced the total outstanding common shares by roughly 25%. We believe that by retiring the shares, the company will be better structured to move forward with it's plans and goals.
BioStem Technologies, Inc. (OTC: BSEM) Announces Issuance of FDA Drug Establishment Registration Number and FDA Labeler Code to Wholly Owned Subsidiary BioStem Pharmaceuticals, Inc.
Marketwired - Thu Jun 02, 8:30AM CDT
OAKLAND PARK, FL--(Marketwired - Jun 2, 2016) - BioStem Technologies, Inc. ("BioStem" or the "Company"
(OTC PINK: BSEM) announced today that the FDA has accepted and issued BioStem Pharmaceuticals, Inc., a wholly owned subsidiary of the Company, its FDA Drug Establishment Registration Number and Labeler Code for Manufacturing and Repackaging of pharmaceutical products. BioStem Technologies, Inc. (OTC: BSEM) Appoints David Wolfe and Dr. Michael Beckwith to Its Advisory Board
Marketwire Canada - Fri May 27, 9:31AM CDT
OAKLAND PARK, FL--(Marketwired - May 27, 2016) - BioStem Technologies, Inc. ("BioStem" or the "Company"
(OTC PINK: BSEM) today announced the appointment of David Wolfe and Rev. Michael Bernard Beckwith to its Advisory Board. The Advisory Board of the Company provides advice and guidance to the Board of Directors of the Company, but Advisory Board members are not Directors of the Corporation. Mr. Wolfe and Dr. Beckwith are both well-known opinion leaders in their respective fields. Biostem Technologies, Inc. (OTC: BSEM) Announces the Appointment of Dr. Dave Woynarowski as Chief Medical Officer
Marketwired - Mon Feb 01, 11:19AM CST
Dr. Dave Woynarowski was appointed Chief Medical Officer of Biostem Technologies, Inc. (OTC PINK: BSEM) effective immediately. Dr. Woynarowski received his medical degree from Temple University, and served as chief resident in his Internal Medicine Training program. He went on to become part of the resident education system, and twice receiving the prestigious Residents Teaching Award from his students and residents. He holds a Master's Degree in Physiology, and was a Certified Personal Trainer during his early medical career. He also served as Adjunct Professor to Hershey School of Medicine.
Biostem Technologies, Inc. (OTC: BSEM) Announces Commencement of International Operations in Guadalajara, Mexico
Marketwired - Thu Jan 28, 8:30AM CST
(OTC PINK: BSEM), Biostem Technologies, Inc. We are pleased to announce that Biostem Technologies, Inc. has entered into an agreement with Dr. Jesus Esparragoza Romano and his team in Guadalajara, Mexico to form the Mexican entity -- Bio ST Holdings, S. de R.L. de C.V. which is a wholly owned subsidiary of Biostem Technologies, Inc.
Biostem Technologies Completes Test-O-Shave Product Line Acquisition
PR Newswire - Fri Dec 11, 8:30AM CST
(OTC: BSEM), Biostem Technologies, Inc. is pleased to announce the acquisition of another product line. Biostem Technologies (BSEM) acquired this asset by virtue of a stock exchange valued at, $155,500. Test-O-Shave is a product line focusing on providing natural grooming and hygiene products. In addition to the men's line of products, Test-O-Shave produces organic soaps, creams, oils, and a women's shave line in development. What sets this product line apart is its natural testosterone boosting ingredients, Pine Pollen and Tribulus.1 It has been shown that bisphenol A (PBA), preservatives and other artificial ingredients can naturally decrease your testosterone levels.1 Therefore; Test-O-Shave, with it's all natural Pine Pollen and Tribulus may increase your natural testosterone levels.1 The Company will immediately re-brand this product line to its Bioshave brand to become the foundation of the Company's retail natural grooming and hygiene products.
Biostem Technologies, Inc. (OTC: BSEM) Announces Purchase of New Laboratory / Headquarters
PR Newswire - Mon Nov 16, 8:30AM CST
(OTC: BSEM), Biostem Technologies, Inc. is pleased to announce the purchase of its new research and development laboratory and headquarters. The building is located at 2836 Center Port Circle in Pompano Beach, FL. With frontage on I-95 and Copans Road, Center Port Business Park is strategically located nearly equidistant from Fort Lauderdale and Miami, to the south, and Boca Raton and West Palm Beach, to the north. The purchase price of Biostem's new laboratory and headquarters was $600,000 and projected build-out costs are estimated to be $700,000. The estimated grand opening for the completed facility is scheduled for March 1st, 2016.
BioStem Technologies Announces the Launch of our New Educational and Interactive Website
ACCESSWIRE - Thu Apr 09, 7:52AM CDT
OAKLAND PARK, FL / ACCESSWIRE / April 9, 2015 / BioStem Technologies, Inc. (OTC PINK: BSEM) announces newly created educational and interactive website set to go live today, April 9, 2015.
BioStem Technologies (BSEM) Announces Retirement of 128,979,751 Shares of Common Stock and the Issuance of Amended Series B-1
ACCESSWIRE - Thu Jan 08, 7:01AM CST
Oakland Park, FL / ACCESSWIRE / January 8, 2015 / Biostem Technologies, Inc. (BSEM), announces that it has officially retired 128,979,751 shares of common stock. Furthermore, the company has amended its Series B-1 shares. The retiring of the 128,979,751 common shares to treasury reduced the total outstanding common shares by roughly 25%. We believe that by retiring the shares, the company will be better structured to move forward with it's plans and goals.
